PerkinElmer (NYSE:PKI) had its target price raised by UBS Group from $99.00 to $101.00 in a research note issued to investors on Tuesday, July 30th, BenzingaRatingsTable reports. They currently have a neutral rating on the medical research company’s stock.
Other equities research analysts have also issued reports about the stock. Raymond James initiated coverage on shares of PerkinElmer in a report on Wednesday, July 10th. They issued an outperform rating for the company. Goldman Sachs Group raised shares of PerkinElmer from a neutral rating to a buy rating and set a $115.00 target price for the company in a report on Tuesday, April 9th. Wolfe Research initiated coverage on shares of PerkinElmer in a report on Thursday, May 30th. They set a peer perform rating for the company. Zacks Investment Research raised shares of PerkinElmer from a hold rating to a buy rating and set a $89.00 price objective for the company in a report on Thursday, May 30th. Finally, Wood & Company reaffirmed an average rating and set a $49.00 price objective on shares of PerkinElmer in a report on Friday, July 19th. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $78.58.
Shares of PerkinElmer stock opened at $80.66 on Tuesday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.89 and a quick ratio of 1.31. The stock has a market cap of $8.98 billion, a price-to-earnings ratio of 22.34, a PEG ratio of 1.44 and a beta of 1.25. The firm’s 50-day moving average is $91.52 and its 200 day moving average is $92.81. PerkinElmer has a 1 year low of $71.83 and a 1 year high of $103.00.
The firm also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 18th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Thursday, October 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.35%. PerkinElmer’s payout ratio is 7.76%.
A number of hedge funds have recently added to or reduced their stakes in PKI. Norges Bank purchased a new stake in PerkinElmer in the fourth quarter worth $66,531,000. Nuveen Asset Management LLC increased its stake in PerkinElmer by 33,237.6% in the second quarter. Nuveen Asset Management LLC now owns 793,435 shares of the medical research company’s stock worth $76,439,000 after purchasing an additional 791,055 shares during the period. BlackRock Inc. increased its stake in PerkinElmer by 10.8% in the second quarter. BlackRock Inc. now owns 7,400,482 shares of the medical research company’s stock worth $712,962,000 after purchasing an additional 721,797 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of PerkinElmer by 1,019.5% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 521,309 shares of the medical research company’s stock valued at $50,223,000 after buying an additional 474,741 shares during the period. Finally, Echo Street Capital Management LLC increased its stake in shares of PerkinElmer by 70.6% during the second quarter. Echo Street Capital Management LLC now owns 900,694 shares of the medical research company’s stock valued at $86,773,000 after buying an additional 372,800 shares during the period. Institutional investors and hedge funds own 96.48% of the company’s stock.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Featured Article: Is a Roth IRA right for you?
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.